Evaluation of electrocardiographic repolarization parameters in patients who received ribociclib and palbociclib therapy

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL
Cennet Yildiz, GülçinSahingöz Erdal, Dilay Karabulut, Nilgun Isiksacan, Ersan Oflar, FatmaNihan Turhan Çaglar, Osman Pirhan, HasanAli Sinoplu, Fahrettin Katkat, Deniz Tural
{"title":"Evaluation of electrocardiographic repolarization parameters in patients who received ribociclib and palbociclib therapy","authors":"Cennet Yildiz, GülçinSahingöz Erdal, Dilay Karabulut, Nilgun Isiksacan, Ersan Oflar, FatmaNihan Turhan Çaglar, Osman Pirhan, HasanAli Sinoplu, Fahrettin Katkat, Deniz Tural","doi":"10.4103/injms.injms_27_23","DOIUrl":null,"url":null,"abstract":"Introduction: Ribociclib and palbociclib are the inhibitors of cyclin-dependent kinase (CDK) 4/6 activity which have been used in the treatment of metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative breast cancer. QT interval prolongation has been the main reported adverse effect in Phase III trials of ribociclib and palbociclib therapy. In the present study, we aimed to evaluate electrocardiographic (ECG) changes in patients who received palbociclib and ribociclib therapy. Materials and Methods: Sixty women with metastatic HR-positive, human epidermal growth factor-2-negative breast cancer were included in the study. Baseline ECG and echocardiographic examinations of these patients were done. Second control electrocardiogram was obtained on the 14th day of first-cycle therapy. PR interval, corrected QT (QTc) interval, QT dispersion (QTD), and QRS duration were calculated. Results: Heart rate, PR interval, QRS, QT, QTc, QTD, and corrected QTD duration did not differ before and after CDK 4/6 treatment. Two patients who received ribociclib and palbociclib treatment had basal QTc duration higher than 450 ms (458 ms and 465 ms, respectively). The 14th-day QTc intervals of these patients were found to be 318 ms and 406 ms, respectively. After CDK 4/6 treatment, only two patients had QTc interval of 469 ms and 507 ms. The mean change of QTc interval before and during the 14th day of CDK 4/6 therapy was 7.38 ± 35.049 ms. When palbociclib and ribociclib treatments were analyzed separately, the baseline and 14th day of QTc interval were 415 ± 31.5 versus 428.11 ± 24.52 and 416.13 ± 26.05 versus 420.07 ± 31.32 ms, respectively. Conclusions: Ribociclib and palbociclib treatment was associated with a small statistically insignificant increase in QTc interval. Physicians should be aware of the side effect of these treatments.","PeriodicalId":43811,"journal":{"name":"Indian Journal of Medical Specialities","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Specialities","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/injms.injms_27_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Ribociclib and palbociclib are the inhibitors of cyclin-dependent kinase (CDK) 4/6 activity which have been used in the treatment of metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative breast cancer. QT interval prolongation has been the main reported adverse effect in Phase III trials of ribociclib and palbociclib therapy. In the present study, we aimed to evaluate electrocardiographic (ECG) changes in patients who received palbociclib and ribociclib therapy. Materials and Methods: Sixty women with metastatic HR-positive, human epidermal growth factor-2-negative breast cancer were included in the study. Baseline ECG and echocardiographic examinations of these patients were done. Second control electrocardiogram was obtained on the 14th day of first-cycle therapy. PR interval, corrected QT (QTc) interval, QT dispersion (QTD), and QRS duration were calculated. Results: Heart rate, PR interval, QRS, QT, QTc, QTD, and corrected QTD duration did not differ before and after CDK 4/6 treatment. Two patients who received ribociclib and palbociclib treatment had basal QTc duration higher than 450 ms (458 ms and 465 ms, respectively). The 14th-day QTc intervals of these patients were found to be 318 ms and 406 ms, respectively. After CDK 4/6 treatment, only two patients had QTc interval of 469 ms and 507 ms. The mean change of QTc interval before and during the 14th day of CDK 4/6 therapy was 7.38 ± 35.049 ms. When palbociclib and ribociclib treatments were analyzed separately, the baseline and 14th day of QTc interval were 415 ± 31.5 versus 428.11 ± 24.52 and 416.13 ± 26.05 versus 420.07 ± 31.32 ms, respectively. Conclusions: Ribociclib and palbociclib treatment was associated with a small statistically insignificant increase in QTc interval. Physicians should be aware of the side effect of these treatments.
接受核博西尼和帕博西尼治疗的患者心电图复极参数的评价
Ribociclib和palbociclib是细胞周期蛋白依赖性激酶(CDK) 4/6活性抑制剂,已被用于治疗转移激素受体(HR)阳性、人表皮生长因子受体2阴性的乳腺癌。QT间期延长是核波西尼和帕博西尼治疗的III期试验中报道的主要不良反应。在本研究中,我们旨在评估接受帕博西尼和核博西尼治疗的患者的心电图(ECG)变化。材料和方法:60例转移性hr阳性、人表皮生长因子-2阴性乳腺癌患者纳入研究。对这些患者进行了基线心电图和超声心动图检查。在第一个周期治疗的第14天获得第二组对照心电图。计算PR间期、校正QT间期、QT离散度、QRS持续时间。结果:cdk4 /6治疗前后心率、PR间期、QRS、QT、QTc、QTD、校正QTD持续时间无显著差异。两名接受核素西尼和帕博西尼治疗的患者的基础QTc持续时间高于450 ms(分别为458 ms和465 ms)。这些患者第14天QTc间隔分别为318 ms和406 ms。CDK 4/6治疗后,仅有2例患者QTc间隔分别为469 ms和507 ms。CDK 4/6治疗前和第14天QTc间隔的平均变化为7.38±35.049 ms。当帕博西尼和核糖西尼治疗单独分析时,基线和第14天QTc间隔分别为415±31.5 ms vs 428.11±24.52 ms和416.13±26.05 ms vs 420.07±31.32 ms。结论:Ribociclib和palbociclib治疗与QTc间期的增加相关,但统计学上不显著。医生应该意识到这些治疗的副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Indian Journal of Medical Specialities
Indian Journal of Medical Specialities MEDICINE, GENERAL & INTERNAL-
自引率
16.70%
发文量
51
期刊介绍: The Indian Journal of Medical Specialities is an all-encompassing peer-reviewed quarterly journal. The journal publishes scholarly articles, reviews, case reports and original research papers from medical specialities specially pertaining to clinical patterns and epidemiological profile of diseases. An important highlight is the emphasis on undergraduate and postgraduate medical education including various aspects of scientific paper-writing. The journal gives priority to research originating from the developing world, including from the tropical regions of the world. The journal also publishes special issues on health topics of current interest. The Indian Journal of Medical Specialities is one of the very few quality multispeciality scientific medical journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信